Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia
| Status: | Completed |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any - 70 |
| Updated: | 11/8/2014 |
| Start Date: | June 2011 |
| End Date: | June 2015 |
| Contact: | Robert A Brodsky, MD |
| Email: | brodsro@jhmi.edu |
| Phone: | 410-502-2546 |
A Phase II Trial of Myeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated (MUD) Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Patients with severe, refractory aplastic anemia have a severe, life threatening disease in
their bone marrow. Refractory disease means that disease has come back or not responded
after receiving one or more immunosuppressive treatments. High dose chemotherapy followed by
bone marrow transplantation (BMT) has been used to treat blood diseases like aplastic anemia
but complications from Graft vs Host disease (GVHD) and graft failure have limited the
survival for those patients.
Another study done here at Johns Hopkins has shown that in patients with other diseases
(blood cancers) some immunosuppressive drugs given after the BMT has decreased how often
patients had complications of GVHD and engraftment failure.
This research is being done to find if this approach will help patients with aplastic anemia
who have failed other treatments will have better outcomes.
their bone marrow. Refractory disease means that disease has come back or not responded
after receiving one or more immunosuppressive treatments. High dose chemotherapy followed by
bone marrow transplantation (BMT) has been used to treat blood diseases like aplastic anemia
but complications from Graft vs Host disease (GVHD) and graft failure have limited the
survival for those patients.
Another study done here at Johns Hopkins has shown that in patients with other diseases
(blood cancers) some immunosuppressive drugs given after the BMT has decreased how often
patients had complications of GVHD and engraftment failure.
This research is being done to find if this approach will help patients with aplastic anemia
who have failed other treatments will have better outcomes.
Inclusion Criteria:
- Patients who have refractory or relapsed SAA following treatment with one or more
immunosuppressive regimens.
- Age 6 months - 70 years
- Patients must meet medical criteria for myeloablative BMT
- Patients or their parents/guardians and donors must be able to sign consent forms.
- Patients must be geographically accessible and willing to participate in all stages
of treatment.
Exclusion Criteria:
- Poor cardiac function: left ventricular ejection fraction <45% as determined by MUGA
or ECHO.
- Poor pulmonary function: FEV1 and FVC <50% predicted.
- Poor renal function
- Positive leukocytotoxic crossmatch
- Women of childbearing potential who currently are pregnant (Β-HCG+) or who are not
practicing adequate contraception
- Uncontrolled viral, bacterial, or fungal infections
We found this trial at
1
site
Click here to add this to my saved trials
